CymaBay Pipeline

Home / Pipeline

Overview

Our pipeline is focused on developing therapies for liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Additionally, we have two drug candidates in early development that feature unique mechanisms of action with potential to treat liver and other chronic diseases.

  Pre-Clinical Phase 1 Phase 2 Phase 3
Internal Programs
Seladelpar
Primary Biliary Cholangitis
Seladelpar
Nonalcoholic Steatohepatitis
Seladelpar
Primary Sclerosing Cholangitis
MBX-2982

(GPR 119 agonist)

Gut/Liver
CB-001

(GPR 120 agonist)

Gut/Liver